Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.11.008Source: DataRank Database

A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI is a research paper published in Journal of Cystic Fibrosis (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.99)OA: bronzeTopics (42)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Lauren Bartlett ORCID,T. Milinic ORCID,Nora Burdis,Joseph M. Pilewski ORCID,Jordan Dunitz ORCID

Live enrichment

PubMed:38008684 OpenAlex:https://openalex.org/W4388997482

National Institutes of Health

Grant: K23HL138154

National Institutes of Health

Grant: P30 DK089507

National Institutes of Health

Grant: T32NR016913

Cystic Fibrosis Foundation

Grant: BOMBER19R0

Cystic Fibrosis Foundation

Grant: RAMOS17A0

Cystic Fibrosis Foundation

Grant: RAMOS20A0-KB

NHLBI NIH HHS

Grant: T32 HL125195

FWCI

0.99

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.cysticfibrosisjournal.com/article/S1569-1993(23)01678-8/pdf

publisherhttps://www.cysticfibrosisjournal.com/article/S1569-1993(23)01678-8/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199323016788?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199323016788?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2023.11.008

Fields of Study

Cystic Fibrosis Research AdvancesTracheal and airway disordersNeonatal Respiratory Health ResearchAdultHumansCystic FibrosisPyrazolesPyridinesLungCystic Fibrosis Transmembrane Conductance RegulatorMutationAminophenolsBenzodioxolesPyrrolidines

MeSH Terms

AdultAminophenolsCystic FibrosisHumansLungMutationPyrazolesPyridinesPyrrolidinesCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxoles

Keywords

MedicineCystic fibrosisIvacaftorRespiratory systemInternal medicineCohortPopulationLung functionLungRespiratory diseaseLung diseaseDiseaseCystic fibrosis transmembrane conductance regulatorEnvironmental healthCystic fibrosis transmembrane conductance regulator modulatorElexacaftor/tezacaftor/ivacaftorRespiratory symptoms

Sustainable Development Goals

SDG 0: Good health and well-being